UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes

Breast cancer research and treatment, 2019-11, Vol.178 (2), p.451-458

2019

Volltextzugriff (PDF)

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

Cancer discovery, 2021-10, Vol.11 (10), p.2474-2487

2021

Volltextzugriff (PDF)

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

JNCI : Journal of the National Cancer Institute, 2012-03, Vol.104 (6), p.441-451

2012

Volltextzugriff (PDF)

Molecular Testing for Targeted Therapy in Advanced Non–Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration

American journal of clinical pathology, 2015-10, Vol.144 (4), p.629-634

2015

Volltextzugriff (PDF)

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Journal of clinical oncology, 2007-09, Vol.25 (25), p.3846-3852

2007

Volltextzugriff (PDF)

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

Breast cancer research and treatment, 2014-02, Vol.143 (3), p.485-492

2014

Volltextzugriff (PDF)

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment

The American journal of surgical pathology, 2018-09, Vol.42 (9), p.1190-1200

2018

Volltextzugriff (PDF)

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

JAMA oncology, 2018-10, Vol.4 (10), p.1335

2018

Volltextzugriff (PDF)

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Breast cancer research and treatment, 2016-02, Vol.155 (3), p.463-469

2016

Volltextzugriff (PDF)

Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies

Applied immunohistochemistry & molecular morphology, 2017-05, Vol.25 (5), p.313-319

2017

Volltextzugriff (PDF)

Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay

Pathology, research and practice, 2016-08, Vol.212 (8), p.735-742

2016

Volltextzugriff (PDF)

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

Breast cancer research and treatment, 2015-06, Vol.151 (2), p.373-384

2015

Volltextzugriff (PDF)

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Breast cancer research and treatment, 2015-12, Vol.154 (3), p.543-555

2015

Volltextzugriff (PDF)

Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples

Journal of Clinical Microbiology, 2006-06, Vol.44 (6), p.2141-2146

2006

Volltextzugriff (PDF)

Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer

Oncotarget, 2016-06, Vol.7 (24), p.37160-37176

2016

Volltextzugriff (PDF)

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

JAMA oncology, 2016-02, Vol.2 (2), p.217

2016

Volltextzugriff (PDF)

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

Breast cancer research and treatment, 2019-08, Vol.176 (3), p.557-568

2019

Volltextzugriff (PDF)

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

The Journal of clinical investigation, 2024-04, Vol.134 (7), p.1-17

2024

Volltextzugriff (PDF)

Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA

Breast cancer research and treatment, 2006-07, Vol.98 (2), p.185-190

2006

Volltextzugriff (PDF)

Ki-67

Breast cancer research and treatment, 2019-11, Vol.178 (2), p.451

2019

Volltextzugriff (PDF)

HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17

European journal of cancer (1990), 2007-11, Vol.43 (16), p.2339-2344

2007

Volltextzugriff (PDF)

Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients

Journal of surgical oncology, 2004-03, Vol.85 (3), p.123-128

2004

Volltextzugriff (PDF)

1 – 25 von 85

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(75)
Mit Volltextzugriff
(71)

Publikationsform

Artikel
(83)
Buchkapitel
(2)

Sprache

Englisch
(85)
Japanisch
(11)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Ki-67 (30-9) scoring and differentiation of Luminal A- and Luminal B-like breast cancer subtypes

Impact of HER2 Heterogeneity on Treatment Response of Early-Stage HER2-Positive Breast Cancer: Phase II Neoadjuvant Clinical Trial of T-DM1 Combined with Pertuzumab

CYP2D6 Genotype and Tamoxifen Response in Postmenopausal Women with Endocrine-Responsive Breast Cancer: The Breast International Group 1-98 Trial

Molecular Testing for Targeted Therapy in Advanced Non–Small Cell Lung Cancer: Suitability of Endobronchial Ultrasound Transbronchial Needle Aspiration

Prognostic and Predictive Value of Centrally Reviewed Expression of Estrogen and Progesterone Receptors in a Randomized Trial Comparing Letrozole and Tamoxifen Adjuvant Therapy for Postmenopausal Early Breast Cancer: BIG 1-98

Prognostic and Predictive Value of Centrally Reviewed Ki-67 Labeling Index in Postmenopausal Women With Endocrine-Responsive Breast Cancer: Results From Breast International Group Trial 1-98 Comparing Adjuvant Tamoxifen With Letrozole

Central pathology laboratory review of HER2 and ER in early breast cancer: an ALTTO trial [BIG 2-06/NCCTG N063D (Alliance)] ring study

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment

Predictive value and clinical utility of centrally assessed ER, PgR, and Ki-67 to select adjuvant endocrine therapy for premenopausal women with hormone receptor-positive, HER2-negative early breast cancer: TEXT and SOFT trials

Association of Somatic Driver Alterations With Prognosis in Postmenopausal, Hormone Receptor–Positive, HER2-Negative Early Breast Cancer: A Secondary Analysis of the BIG 1-98 Randomized Clinical Trial

Discordant assessment of tumor biomarkers by histopathological and molecular assays in the EORTC randomized controlled 10041/BIG 03-04 MINDACT trial breast cancer: Intratumoral heterogeneity and DCIS or normal tissue components are unlikely to be the cause of discordance

Immunohistochemical Performance of Estrogen and Progesterone Receptor Antibodies on the Dako Omnis Staining Platform: Evaluation in Multicenter Studies

Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial

Assessment of HER2 amplification status in breast cancer using a new automated HER2 IQFISH pharmDx™ (Dako Omnis) assay

CYP19A1 polymorphisms and clinical outcomes in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1–98 trial

ESR1 and ESR2 polymorphisms in the BIG 1-98 trial comparing adjuvant letrozole versus tamoxifen or their sequence for early breast cancer

Comparison of the Digene HC2 Assay and the Roche AMPLICOR Human Papillomavirus (HPV) Test for Detection of High-Risk HPV Genotypes in Cervical Samples

Sensitive and affordable diagnostic assay for the quantitative detection of anaplastic lymphoma kinase (ALK) alterations in patients with non-small cell lung cancer

The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence

Clinical and analytical validation of Ki-67 in 9069 patients from IBCSG VIII + IX, BIG1-98 and GeparTrio trial: systematic modulation of interobserver variance in a comprehensive in silico ring trial

HER2 heterogeneity and treatment response-associated profiles in HER2-positive breast cancer in the NCT02326974 clinical trial

Assessing the status of axillary sentinel lymph nodes of breast carcinoma patients by a real-time quantitative RT-PCR assay for mammaglobin 1 mRNA

Ki-67

HER2 status in early breast cancer: Relevance of cell staining patterns, gene amplification and polysomy 17

Histopathologic examination of axillary sentinel lymph nodes in breast carcinoma patients

Suchergebnisse filtern